Roche-Lestienne C - Search Results

1

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.

Rose C, Dupire S, Roche-Lestienne C, Grardel N, Bourgeois E, Cambier N, Preudhomme C. Rose C, et al. Leukemia. 2004 Feb;18(2):354-5. doi: 10.1038/sj.leu.2403229. Leukemia. 2004. PMID: 14671642 No abstract available.

2

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Laï JL, Philippe N, Facon T, Fenaux P, Preudhomme C. Roche-Lestienne C, et al. Blood. 2002 Aug 1;100(3):1014-8. doi: 10.1182/blood.v100.3.1014. Blood. 2002. PMID: 12130516 Free article.

3

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

Roche-Lestienne C, Laï JL, Darré S, Facon T, Preudhomme C. Roche-Lestienne C, et al. N Engl J Med. 2003 May 29;348(22):2265-6. doi: 10.1056/NEJMc035089. N Engl J Med. 2003. PMID: 12773665 No abstract available.

4

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

Roche-Lestienne C, Preudhomme C. Roche-Lestienne C, et al. Semin Hematol. 2003 Apr;40(2 Suppl 2):80-2. doi: 10.1053/shem.2003.50046. Semin Hematol. 2003. PMID: 12783380 Review.

5

[Origin of resistance to Imatinib mesylate: lessons learned from this experience].

Roche-Lestienne C, Mahon FX, Preudhomme C. Roche-Lestienne C, et al. Med Sci (Paris). 2004 Dec;20(12):1125-30. doi: 10.1051/medsci/200420121125. Med Sci (Paris). 2004. PMID: 15581468 Free article. Review. French.

6

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Roche-Lestienne C, Darré S, Laï JL, Facon T, Guilhot J, Preudhomme C. Roche-Lestienne C, et al. Haematologica. 2005 Jan;90(1):131-3. Haematologica. 2005. PMID: 15642682

7

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Laï JL, Hachulla E, Drupt F, Demarty AL, Roumier AS, Gardembas M, Dib M, Philippe N, Cambier N, Barete S, Libersa C, Bletry O, Hatron PY, Quesnel B, Rose C, Maloum K, Blanchet O, Fenaux P, Prin L, Preudhomme C. Roche-Lestienne C, et al. Leukemia. 2005 May;19(5):792-8. doi: 10.1038/sj.leu.2403722. Leukemia. 2005. PMID: 15772698

8

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

Corm S, Biggio V, Roche-Lestienne C, Laï JL, Yakoub-Agha I, Philippe N, Nicolini FE, Facon T, Preudhomme C. Corm S, et al. Leukemia. 2005 Nov;19(11):1991-2. doi: 10.1038/sj.leu.2403931. Leukemia. 2005. PMID: 16151468 No abstract available.

9

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).

Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P, Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C. Nicolini FE, et al. Leukemia. 2006 Jun;20(6):1061-6. doi: 10.1038/sj.leu.2404236. Leukemia. 2006. PMID: 16642048

10

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

Nicolini FE, Corm S, Lê QH, Roche-Lestienne C, Preudhomme C. Nicolini FE, et al. Leukemia. 2007 Feb;21(2):193-4. doi: 10.1038/sj.leu.2404490. Leukemia. 2007. PMID: 17251899 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters